Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD4831 in Healthy Japanese and Chinese Volunteers
NCT04232345Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (6 arms), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events (AEs)/serious adverse events up to 9 weeks, Number of subjects with abnormal blood pressure (BP) and pulse up to 9 weeks and 2 more. Started Jan 2020; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04232345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232345.